Quant Bro

Tech/Pharma Investor: Please do your own due diligence

[Quant Bro @Quantbro1]

We bought some $chrs: lets see how the cards unfold. Easy 2x from here imo. Lots of opportunities for them to grow.

[Quant Bro @Quantbro1]

@Driller562 Wym not good interview? All he did was just bring up the pipeline and mention readouts. Tagmo and Casdo readouts are imminent.

[Quant Bro @Quantbro1]

@BillMiller32 You can’t get mad at no growth in pharma. Developing drugs takes time and the time for the growth of this stock is when the data comes out. There can’t be growth when you are developing a brand new pipeline and all of your drugs are ph1/2.

[Quant Bro @Quantbro1]

@walststocker @commonsenseplay $flut not doing so strong.

[Quant Bro @Quantbro1]

Sorry guys for not posting recently. I have been busy doing research on pharma companies. I’ll try to keep you guys more informed on my next buys and price targets. Thanks for the patience.

[Quant Bro @Quantbro1]

Fury gonna fuck up AJ

[Ring Magazine @ringmagazine]

✅ DONE DEAL ✅

🥊 Tyson Fury vs Anthony Joshua
📆 Q4, 2026
📺 Netflix

[Quant Bro @Quantbro1]

@JesseCohenInv 2 mill isn’t generational wealth my brotha

[Ring Magazine @ringmagazine]

THIS MOMENT 🍿👀

[Quant Bro @Quantbro1]

$Chrs expect readouts within the next 30-90 days. Lots of shots on goal for them to succeed. They conveniently rally the stock up before readouts. Strange.

[Quant Bro @Quantbro1]

$Irwd: we crushed it today. This was a much needed day after the dive down from the 5’s.

[Quant Bro @Quantbro1]

$Srpt bottomed out. Good buying opportunity for people who are long the stock.

[Quant Bro @Quantbro1]

$Chrs is going to linger in the 1.60-$2.00 range until data. Unless a partnership or price target increase is brought up I don’t see it going up more than $2. Great for high frequency traders though.

[Teton Bio @tetonbio]

$KOD GLOW2 (Q1’26): This result was a decisive validation. 62.5% ≥2-step DRSS improvement vs 3.3% sham with clean safety (0% IOI) moves tarcocimab from comeback to real DR franchise.

The debate is no longer “does it work?” but “how big can this get?”

With 30M+ diabetics in the US and no approved DR-only SOC, this now looks like a low-burden anti-VEGF with >$2B peak sales potential. We’re raising our base valuation to ~$4B on DR alone.
Near-term: $40s–$50s is reasonable as DR gets re-rated. ~20% short float + tight ownership = reflexive move.

If DAYBREAK hits: this becomes a full retina platform story. Path to $100 by year-end is now on the table with DR validated + AMD upside.

[Quant Bro @Quantbro1]

@ForPlanetPluto Do you know what your talking about? You said the stock would go up off this data 15-20% initially. This is counterintuitive to your original tweet.

[Quant Bro @Quantbro1]

$Kod I don’t think I have ever lost on a trade looking back. I’ve always made on every trade I got into.

[Quant Bro @Quantbro1]

$Srpt great day. The floor had to be somewhere. My price target is around $35 a share. Gene therapy for the most part is hard to succeed in (No one has figured it out yet) but I see the company hitting my target.

[Quant Bro @Quantbro1]

@ForPlanetPluto The stock went to over $130 with the same drugs in ph3 during 2020. Also DR is also a big market too just a little lower than Wet amd.

[Quant Bro @Quantbro1]

@ForPlanetPluto 10-20%??? Way more than that. My assumption is the stock goes to $40+. The gap is at $50 which is conveniently where UBS slapped their price target.

[Quant Bro @Quantbro1]

$Whwk easy double from here.

[Quant Bro @Quantbro1]

$Whwk easy double from here. It’s a joke how low valued the company is. HWK-007 will make it to ph2 and the company is going to gain back investor confidence. There is the reason the short interest is at 3.5%. DYOR!